Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration.
about
Lanthanum carbonate for the control of hyperphosphatemia in chronic renal failure patients: a new oral powder formulation - safety, efficacy, and patient adherenceLanthanum associated abnormal liver function tests in two patients on dialysis: a case report.Treatment options of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease stages 3 and 4: an historic review.Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial.Protection of Chinese herbs against adenine-induced chronic renal failure in rats.Pharmacology, efficacy and safety of oral phosphate binders.Pharmacology of the phosphate binder, lanthanum carbonateEfficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic reviewDo aluminium-based phosphate binders continue to have a role in contemporary nephrology practice?Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate.Management of hyperphosphataemia in chronic kidney disease-challenges and solutionsCurrent treatment options in secondary renal hyperparathyroidism.Npt2b deletion attenuates hyperphosphatemia associated with CKD.Phosphate binders: new products and challenges.The safety of phosphate binders.Therapeutic strategies for secondary hyperparathyroidism in dialysis patients.Emerging drugs for hyperphosphatemia.Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trialSevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysisVascular calcification in chronic kidney disease: Pathogenesis and clinical implicationPreclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide.Attempting to build solid recommendations on a shaky evidence base.Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis--an autopsy-based review.Mineral and bone disorders in children with chronic kidney disease.Lanthanum(III) impacts on metallothionein MTT1 and MTT2 from Tetrahymena thermophila.Advances in pharmacotherapy for hyperphosphatemia in renal disease.Hyperphosphatemia among end-stage renal disease patients in developing countries: a forgotten issue?Treating hyperphosphatemia - current and advancing drugs.Possibility of lanthanum absorption in the stomach.Gastric lanthanosis (lanthanum deposition) in dialysis patients treated with lanthanum carbonate.Lanthanum carbonate possibly responsible for acute liver failure in a patient with Child-Pugh stage A liver cirrhosisA confusional state associated with use of lanthanum carbonate in a dialysis patient: a case report.Molecular mechanism of oxidative damage of lung in mice following exposure to lanthanum chloride.Long-term treatment with lanthanum carbonate reduces mineral and bone abnormalities in rats with chronic renal failureAcute functional neurotoxicity of lanthanum(III) in primary cortical networks.Endothelin A receptor blocker and calcimimetic in the adenine rat model of chronic renal insufficiency.Lanthanum deposition in a dialysis patient.Adequate phosphate binding with lanthanum carbonate attenuates arterial calcification in chronic renal failure rats.Severe hyperparathyroidism with bone abnormalities and metastatic calcification in rats with adenine-induced uraemia.Nephroprotective effects of Isaria felina in rats with adenine-induced chronic renal failure.
P2860
Q27013882-D49B78B9-B1A8-447C-BD5A-298735E5B387Q33580114-19C4701F-299E-4AF5-82C5-4D32C0973160Q33610289-74C5E9A9-77AD-4DB1-A456-CE4159B1422CQ33770086-B7BC37B3-4C98-4D05-8218-A4A8447F911CQ33951835-22946BA4-F731-49EA-84AF-FB5351CD2BE6Q34213752-366DBA88-371B-4C8B-A546-B48425B0CADEQ34854318-628FC5F7-D959-4822-8320-F1A91C392C9DQ35019709-0ACF0110-A3DD-4821-9DCE-A43E371D4D7DQ35021546-45D581F7-7B69-411D-B9ED-0CDBA837D57BQ35026657-25971324-2D06-4680-9D87-B95C83BD0560Q35608435-C18342CD-C59F-4475-8112-D24C2404AD0BQ36250191-EDBCBAEF-CE2B-4484-9C88-6328976AE1D7Q36280326-A02325AD-65A3-48F9-AE65-5BC1C46C5158Q36522027-49CF3586-1EEF-4E12-B431-5E338215052DQ36565049-AFB91781-A459-497D-BE44-CF1A6AE17E33Q36566674-B6D7D38F-0C03-4926-BA59-FF790D356C30Q36944004-C0013157-C353-4436-AB69-90E41330EEFBQ37042040-FFF8B929-7963-4E62-B3DD-FCA347CA7FC7Q37052751-0667413C-867B-4C55-BE82-889EEDAB2E86Q37195354-5B8157B2-CBA7-4EB5-B3FC-1B9F56617CB8Q37204047-11BCF41A-DFF1-4F96-8B99-36913D6848DFQ37845416-A4F4EB2F-F392-493E-9AA9-F38309EC6358Q37858286-039DEF5C-0CBD-4926-BBEC-0FE8FAF4B4D6Q37938689-74D27482-C47B-49C0-8028-BBE3A29DBFA8Q38337020-7A03DD9D-F098-43CC-AE7F-A654F6313724Q38587575-A4A8D6B8-6C32-4318-B0EA-3D36E1F777A4Q38861577-707C39A7-5BD4-4B8A-9C23-62692ACB827EQ38958363-8BDAE02B-687D-427A-862F-7D28F65E0225Q38959324-5BEF39A6-263B-47CA-8C1B-22C6E4D1CF0EQ40153866-10B170A5-C742-47C2-91CD-4D738FA55EFFQ41087098-EDFD51E1-34C5-4109-8307-EACD79CED8BAQ42590547-D65FC4E5-A3C1-4642-AF59-70FE3537F6A6Q42708810-C5D9702A-0190-463B-B5D8-D74ABBED39A0Q42745707-A5C00318-D3B3-420A-8FDA-5D7A04641492Q42773959-EAD35A7C-3278-4955-A0AB-702769C62C2FQ43237868-95272D88-1FB4-4708-903F-92DEE1A1723BQ45922756-681139CB-44F7-4DF9-8FBD-893DF1AF0E9DQ46162426-8198190B-802E-4F15-9149-94E4D09FBE95Q46823232-28532CE3-AAFD-4BE0-A7E3-A87D098D7D0BQ47828204-9E3A0FB8-2FA3-4850-8270-DDB787F16F34
P2860
Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Chronic renal failure is assoc ...... er 28-day oral administration.
@en
Chronic renal failure is assoc ...... er 28-day oral administration.
@nl
type
label
Chronic renal failure is assoc ...... er 28-day oral administration.
@en
Chronic renal failure is assoc ...... er 28-day oral administration.
@nl
prefLabel
Chronic renal failure is assoc ...... er 28-day oral administration.
@en
Chronic renal failure is assoc ...... er 28-day oral administration.
@nl
P2093
P1433
P1476
Chronic renal failure is assoc ...... er 28-day oral administration.
@en
P2093
Anthony Lucas
Bernard Lacour
Daniel Auchère
Nadya Ruellan
Natalie Mariaud de Serre Patey
Tilman B Drüeke
P304
P356
10.1111/J.1523-1755.2005.00171.X
P407
P577
2005-03-01T00:00:00Z
P5875
P6179
1033047030